Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Eurofins Ntd Llc |
RCV000656839 | SCV000227691 | uncertain significance | not provided | 2015-11-11 | criteria provided, single submitter | clinical testing | |
Gene |
RCV000656839 | SCV000240814 | uncertain significance | not provided | 2023-07-01 | criteria provided, single submitter | clinical testing | Not observed at significant frequency in large population cohorts (gnomAD); In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; Has not been previously published as pathogenic or benign to our knowledge; This variant is associated with the following publications: (PMID: 27535533, 22872700, 18179895) |
Fulgent Genetics, |
RCV000515351 | SCV000611463 | uncertain significance | Autism, susceptibility to, 15; Cortical dysplasia-focal epilepsy syndrome | 2022-01-28 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV000801308 | SCV000941080 | uncertain significance | Cortical dysplasia-focal epilepsy syndrome | 2022-07-25 | criteria provided, single submitter | clinical testing | This sequence change replaces arginine, which is basic and polar, with cysteine, which is neutral and slightly polar, at codon 1119 of the CNTNAP2 protein (p.Arg1119Cys). This variant is present in population databases (rs367664952, gnomAD 0.02%). This missense change has been observed in individual(s) with clinical features of CNTNAP2-related conditions (Invitae). ClinVar contains an entry for this variant (Variation ID: 195509). Algorithms developed to predict the effect of missense changes on protein structure and function (SIFT, PolyPhen-2, Align-GVGD) all suggest that this variant is likely to be disruptive. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Ambry Genetics | RCV002321694 | SCV002606170 | uncertain significance | Inborn genetic diseases | 2021-10-29 | criteria provided, single submitter | clinical testing | The c.3355C>T (p.R1119C) alteration is located in exon 20 (coding exon 20) of the CNTNAP2 gene. This alteration results from a C to T substitution at nucleotide position 3355, causing the arginine (R) at amino acid position 1119 to be replaced by a cysteine (C). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |